NEO stock: buy or sell?
May 26th, 2020
NeoGenomics, Inc., together with its subsidiaries, operates a network of cancer-focused genetic testing laboratories providing genetic and molecular testing services to hospitals, pathologists, oncologists, urologists, other clinicians and researchers, and other laboratories in the United States.
Should I buy NEO stock?Even if you are a experienced or a novel trader, best trading results come from using an investing strategy that never leaves to random or subjective opinions when is the best moment to buy or sell stocks. Having a trading strategy helps to make decisions easier, quicker and with less hesitations. There are thousands of trading strategies for you to choose, but at Stocks2.com we prefer those that are simple but successful.
None of our preferred buy setups matches with NeoGenomics stock situation right now, therefore this is not a suitable entry point.
|New all-time high||No|
|New 52 week high||No|
|Price crossing up 200d MA||No|
|100d MA crossing up 200d MA||No|
Is NeoGenomics stock a buy?
Everyday, hundreds of stock ratings are published by financial analysts to indicate a particular stock's attractiveness.Unfortunately, we couldn't find any rating for NEO stock for the last month.
NEO stock analysis
NeoGenomics shares collapsed -3.37% to $27.23 today.
Shares of NeoGenomics closed today at $27.23 and collapsed a godawful -3.37%. On May 5th NEO price bounced up over the SMA of 200 days demonstrating to be a significant support for this stock. From a daily perspective, NEO is in a short term uptrend after plotting its last bottom ($26.30, on May 13th) higher than the previous bottom, and its last top ($28.99, on May 18th) also over the previous top. Now trading in between its last bottom and last top NEO might consolidate in a plain range, waiting to break out over $28.99 or down under $26.30. On February, NEO hit a new all time high, pushing higher than on February tops. Check different trading setups that use ATHs as triggers.
NeoGenomics eased an awful -3.37% this week. Late April NEO plunged a hair-raising -14.35% in just one week. Early May NEO skyrocketed an amazing 7.47% in just one week.
Since price and SMA40w lines crossed up early May, NEO climbed $1.23 (4.73%). Not so far away is the last all-time high NeoGenomics marked by mid February, but since then it dropped a 22.13%.
NEO stock price history
NEO stock went public on March 16th, 2004 with a price of $0.571. Since then, NEO stock surged a 4,677.20%, with a yearly average of 292.30%. If you had invested right after NEO's IPO a $1,000 in NEO stock in 2004, it would worth $46,772.00 today.
1: Adjusted price after possible price splits or reverse-splits.
NEO stock historical price chart
NEO stock reached all-time highs on February with a price of $34.97.
NEO stock price targetPredicting the price evolution of a stock or any financial instrument in a reliable and repeatable way is probably impossible. However, many stock price predictions are published every day by banks, financial institutions and independent analysts. We do not recommend to follow these stock price predictions without a critical thinking from your side, as their accuracy is usually low. For the last 30 days we have not detected any price forecast for NeoGenomics stock by any trusted analyst.
Financials and fundamental analysis
Earnings date and Earnings per Share, when NeoGenomics presented its last earnings report, it . Unfortunately, reported EPS is not yet available in our database.
|Quarter||Reporting date||Estimated EPS||Actual EPS||Surprise|
Annual financial resultsIn 2018, NeoGenomics annual turnover climbed an extraordinary 15.19% to $276.74 M USD from $240.25 marked in 2017. When comparing 2018 vs 2017, instead, profit margin (that is, the net income divided by revenues) inched a 1.12% to 0.95%.
|2013||$66 M||-||$2.03 M3.1%||-|
|2014||$87 M||30.99%||$1.13 M1.3%||-44.24%|
|2015||$100 M||14.62%||$-2.54 M-2.5%||-323.94%|
|2016||$244 M||144.57%||$-5.72 M-2.3%||125.76%|
|2017||$240 M||-1.57%||$-0.40 M-0.2%||-93.08%|
|2018||$277 M||15.19%||$2.64 M1.0%||-766.67%|
Quarterly financial resultsNeoGenomics reported $76.48 million in revenues for 2018-Q4, a 10.68% up compared to previous quarter. Reported quarter income marked $0.35 million with a profit margin of 0.46%. Profit margin decreased a -2.47% compared to previous quarter when profit margin was 2.93%. When comparing sales to same quarter last year, NeoGenomics sales marked a fatal drop down and declined a -4.14%. Looking back to recent quarterly results, NeoGenomics posted 3 negative quarters in a row.
|2017-Q2||$66 M||-||$-0.04 M-0.1%||-|
|2017-Q3||$63 M||-4.60%||$-5.10 M-8.1%||11,760.47%|
|2017-Q4||$80 M||26.54%||$4.10 M5.1%||-180.35%|
|2018-Q1||$63 M||-20.50%||$0.64 M1.0%||-84.29%|
|2018-Q2||$68 M||6.82%||$-0.38 M-0.6%||-159.01%|
|2018-Q3||$69 M||1.99%||$2.02 M2.9%||-632.37%|
|2018-Q4||$76 M||10.68%||$0.35 M0.5%||-82.55%|
|2019-Q1||$96 M||24.98%||$-2.42 M-2.5%||-786.69%|
NeoGenomics ownershipChecking NeoGenomics ownership structure gives valuable information about the company and its governance (insider ownership) or the amount of investors that are on the short side.
NeoGenomics shares owned by insiders (that is, founders, CEO, CTO, main executives or other management staff) currently counts a 5.89% of all shares.
Bearish positions for NEO stock account 0.00%, no big difference from last month.
For a better context understanding, the following table shows ownership data compared to other related companies:
|Market cap||$3.0 B|
|Total shares||109.7 M|
|Float shares||101.6 M|
|- Institutional holdings (%)||85.1%|
|- Insider holdings (%)||5.9%|
|Shares in short selling||0.0%|
|Tuesday, May 26th, 2020|
|Day range||$27.10 - $29.10|
|Average true range||$1.12|
|50d mov avg||$27.15|
|100d mov avg||$29.07|
|200d mov avg||$26.35|
NeoGenomics performanceStocks performance is always measured in comparision to the market or competitors and related stocks in the same industry. For NeoGenomics, the comparison is made against .